IL-18, also known as Interferon-gamma Inducing Factor (IGIF), is widely recognized for its potential value in immune regulation and anti-tumor immunotherapy. It has been extensively explored in the development of therapeutic drugs for various cancers, infectious diseases, autoimmune diseases, and inflammatory bowel disease. Today, we present a case study of Nanobody Development by NBLST targeting IL-18.

GLP-1R (Glucagon-like peptide-1 receptor) has long been a prominent target in the field of diabetes. It is a hormone primarily produced by L cells in the intestine and belongs to the incretin family. Agonists of its receptor reduce appetite and food intake, thereby lowering blood sugar levels, which has garnered considerable attention worldwide. Today, we present a case study on the independent development of nanobodies targeting GLP-1R by NBLST.

Nano Body  Life Sciences and Technology - NBLST : A Case Study on the Development of Nanobodies Targeting the Spike Protein of the Novel Coronavirus, Sharing the Process, Results, and Applications of this Nanobody. The development process of this case study comprises six key stages: immunization of alpacas, construction of phage display libraries, screening and identification of positive monoclonal nanobody-expressing microbes via phage surface display, recombinant expression, purification, and testing of positive monoclonal nanobodies, identification of antibody binding sites, and neutralizing antibody detection

       NBLST Laboratory has independently developed an effective Anti-CaSR nanobody product, targeting CaSR. This product assists researchers in optimizing experimental outcomes and providing new avenues for studying the activation mechanism of CaSR and its relevance to various disorders associated with Ca2+ dysfunction.